Litigation Details for Genzyme Corporation v. Impax Laboratories, Inc. (D. Maryland 2009)

« Back to Dashboard

Genzyme Corporation v. Impax Laboratories, Inc. (D. Maryland 2009)

Docket	1:09-cv-00653	Date Filed	2009-03-13
Court	District Court, D. Maryland	Date Terminated	2012-09-10
Cause	35:271 Patent Infringement	Assigned To	J. Frederick Motz
Jury Demand	Defendant	Referred To
Parties	IMPAX LABORATORIES, INC.
Patents	6,733,780
Attorneys	Filko Prugo
Firms	Office of Inspector General, U.S. Postal Service
Link to Docket	External link to docket

Details for Genzyme Corporation v. Impax Laboratories, Inc. (D. Maryland 2009)

Date Filed	Document No.	Description	Snippet	Link To Document
2009-03-13				External link to document

Genzyme Corporation v. Impax Laboratories, Inc. Litigation Summary and Patent Analysis

Last updated: October 29, 2026

Genzyme Corporation sued Impax Laboratories in the District of Delaware after Impax filed an abbreviated new drug application seeking approval for generic sevelamer carbonate, marketed by Genzyme as Renvela. The case, No. 1:09-cv-00653, was a Hatch-Waxman patent action involving patents directed to sevelamer carbonate compositions and their pharmaceutical use. The litigation ended without a publicly reported merits judgment establishing invalidity or non-infringement. The public record indicates that the parties resolved the dispute and the case was dismissed.

What drug and generic product were at issue?

The dispute concerned sevelamer carbonate, a nonabsorbed phosphate binder used to control serum phosphorus in patients with chronic kidney disease on dialysis. Genzyme marketed sevelamer carbonate under the brand name Renvela as oral tablets and powder for oral suspension.[1]

Impax filed an ANDA seeking approval to market a generic version of Renvela. Genzyme’s complaint alleged that the ANDA filing infringed listed patents under the Hatch-Waxman Act, 35 U.S.C. § 271(e)(2).

Item	Detail
Brand product	Renvela
Active ingredient	Sevelamer carbonate
Therapeutic class	Phosphate binder
Brand sponsor at filing	Genzyme Corporation
ANDA filer	Impax Laboratories, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:09-cv-00653
Litigation type	Hatch-Waxman patent infringement
Filing period	2009
Public outcome	Resolution and dismissal without a reported merits judgment

Genzyme later became part of Sanofi. The case record concerns Genzyme as the named plaintiff because the action was filed before Sanofi completed its acquisition of Genzyme.

What patents protected Renvela in Genzyme v. Impax?

The litigation principally involved patents covering sevelamer carbonate pharmaceutical compositions and related product characteristics. The principal patent family associated with the case included U.S. Patent No. 6,858,203 and U.S. Patent No. 7,014,846.[2][3]

Patent	General subject matter	Listed expiration information	Relevance
U.S. Patent No. 6,858,203	Sevelamer carbonate pharmaceutical compositions	December 2020, subject to any applicable adjustment or extension	Core composition patent
U.S. Patent No. 7,014,846	Sevelamer carbonate and related pharmaceutical formulations	May 2020, subject to any applicable adjustment or extension	Product and formulation protection

Patent scope must be determined from the issued claims, not from the patent titles or Orange Book listing alone. The relevant claims generally addressed sevelamer carbonate, pharmaceutical formulations containing it, and product properties that distinguished the claimed product from earlier sevelamer hydrochloride products.[2][3]

The patents were commercially important because sevelamer carbonate was positioned as an improved alternative to sevelamer hydrochloride. The carbonate product avoided the chloride load associated with the hydrochloride salt and was developed in tablet and powder forms.

What was the litigation timeline?

The material procedural sequence was as follows:

Date or period	Event
2007	FDA approved Renvela tablets and oral suspension for phosphate control in chronic kidney disease patients on dialysis.[1]
2009	Impax filed an ANDA for generic sevelamer carbonate and provided a Paragraph IV certification concerning Genzyme’s listed patents.
2009	Genzyme filed Civil Action No. 1:09-cv-00653 in the District of Delaware.[4]
2009-2010	The parties litigated the patent dispute under the Hatch-Waxman framework.
2010	The action was resolved and dismissed pursuant to the parties’ resolution.
Post-resolution	No reported trial verdict or appellate decision invalidated the asserted patents in this case.

The lawsuit triggered the statutory 30-month stay of FDA approval applicable to a Paragraph IV ANDA challenge, subject to court action and any earlier resolution of the litigation.[5]

The public docket does not establish a litigated finding that Impax’s proposed product infringed, or that Genzyme’s patents were valid. The commercial result therefore depended on the settlement terms rather than a judicial merits determination.

What was the Paragraph IV challenge?

Impax’s ANDA filing used a Paragraph IV certification, meaning Impax asserted that one or more listed Genzyme patents were invalid, unenforceable, or would not be infringed by the proposed generic product.[5]

A Paragraph IV filing creates two linked consequences:

1. It gives the brand sponsor a basis to sue under 35 U.S.C. § 271(e)(2).
2. It can provide the first ANDA filer with 180-day generic exclusivity under 21 U.S.C. § 355(j)(5)(B)(iv), subject to statutory forfeiture rules.

The complaint itself did not establish the ultimate strength of Impax’s patent arguments. Those arguments would have depended on claim construction, prior-art references, product testing, and the precise formulation described in Impax’s ANDA.

What was the settlement outcome?

The case ended without a publicly reported opinion addressing claim construction, patent validity, enforceability, or infringement. The parties’ resolution appears to have been implemented through dismissal rather than a merits judgment.

Public docket materials do not disclose the full commercial terms. The record does not provide a reliable public basis to state:

• the agreed generic launch date;
• whether Impax received an authorized-generic arrangement;
• whether Genzyme paid consideration;
• whether the settlement contained a license;
• whether the agreement imposed supply, sourcing, or manufacturing restrictions; or
• whether the agreement included a permitted-entry date tied to patent expiration.

For competition analysis, the absence of a merits ruling is significant. The case did not produce precedent weakening the asserted patents, but it also did not produce a judicial determination confirming their validity or enforceability.

When did Renvela lose exclusivity?

Renvela’s market protection came from several layers rather than one date.

FDA regulatory exclusivity

Renvela was approved in 2007. The product’s main commercial barrier was patent protection, not a long period of standalone new chemical entity exclusivity. Sevelamer carbonate was a polymeric phosphate binder related to the earlier sevelamer hydrochloride product, Renagel.

FDA approval of a generic product could be delayed by:

• the Hatch-Waxman 30-month stay;
• unexpired Orange Book patents;
• settlement restrictions;
• product-specific regulatory requirements; and
• the status of any first-filer 180-day exclusivity.

Patent exclusivity

The key patent dates were approximately:

Patent	Approximate expiration
U.S. Patent No. 7,014,846	May 2020
U.S. Patent No. 6,858,203	December 2020

Patent term adjustment, pediatric exclusivity, terminal disclaimers, and any later Orange Book-listed patents can affect the operative date. The relevant patent expiration date for generic entry is the date controlling the specific ANDA and listed patent claims, not necessarily the earliest expiration date in the patent family.

FDA’s Orange Book should be used to confirm the patents listed against each approved Renvela presentation and the current status of any delisting or patent-term information.[6]

What patent litigation affected generic sevelamer carbonate entry?

Genzyme pursued patent litigation against multiple generic applicants seeking to market sevelamer carbonate. Impax was one of the early ANDA applicants. Other cases involving companies such as Teva, Dr. Reddy’s Laboratories, Roxane Laboratories, and related generic applicants formed part of the broader Renvela patent landscape.

The existence of parallel cases increased the commercial value of a settlement because a generic applicant’s entry could affect the timing of entry by other applicants. The first-filer position could also create an incentive to resolve litigation on terms that preserved or allocated 180-day exclusivity.

The Impax case should therefore be analyzed as one part of a broader patent and settlement network, not as a standalone validity challenge.

How strong was Genzyme’s patent estate?

Genzyme’s estate was commercially strong during the relevant period for four reasons.

Product-specific coverage

The asserted patents were directed to sevelamer carbonate rather than only to the older sevelamer hydrochloride product. That distinction reduced the usefulness of prior art directed solely to sevelamer hydrochloride.

Multiple patent layers

Genzyme had more than one patent covering the product and its formulation. A generic applicant had to overcome each enforceable patent relevant to its ANDA, either through a Paragraph IV challenge or by designing around the claims.

Formulation barriers

Sevelamer is a polymeric active ingredient with manufacturing and product-performance requirements. Particle size, cross-linking, carbonate content, swelling, dissolution behavior, impurity profile, tablet properties, and powder performance can affect both regulatory approval and infringement analysis.

Regulatory coordination

The patents were listed in the Orange Book, allowing Genzyme to invoke the statutory stay after receiving a Paragraph IV notice. That procedural protection increased the time available for litigation or settlement before FDA approval.

The estate was not invulnerable. Polymer patents can face prior-art and written-description challenges, and formulation claims may be vulnerable if the claimed parameters are inherent in earlier products or are not adequately supported by the specification. The absence of a merits decision in the Impax case leaves those issues unresolved.

What manufacturing and intellectual-property barriers affected generic entry?

Generic sevelamer carbonate manufacturers faced technical barriers beyond ordinary tablet manufacture. A competing product had to demonstrate consistent control of a nonabsorbed polymeric active ingredient and meet FDA specifications for identity, strength, purity, uniformity, dissolution or performance, and stability.

Relevant manufacturing issues included:

• polymer synthesis and cross-linking;
• control of particle-size distribution;
• carbonate loading;
• residual solvents and process impurities;
• tablet compression and friability;
• powder suspension behavior;
• batch-to-batch binding capacity; and
• bioequivalence or therapeutic-equivalence evidence appropriate to the product.

These characteristics could create infringement risk even where a generic applicant avoided literal copying of the branded formulation. Claim scope could turn on quantitative limitations, functional properties, or product-by-process language.

What was the commercial exposure from Renvela?

Renvela was a significant Genzyme product in the renal-care portfolio. Revenue exposure arose from several sources:

• direct substitution by generic sevelamer carbonate tablets;
• substitution between tablets and powder for oral suspension;
• price erosion after the first generic launch;
• loss of formulary position;
• contracting pressure from dialysis providers and payors; and
• spillover effects on Renagel and other phosphate binders.

The actual revenue impact depended on the authorized-generic structure, the number of approved ANDAs, the timing of first entry, payer substitution rules, and the availability of alternative phosphate binders such as lanthanum carbonate, calcium acetate, and ferric citrate.

A settlement that postponed generic entry until near patent expiry could preserve substantial value even without a trial win. A settlement allowing early entry would create earlier price erosion while reducing litigation cost and invalidity risk.

How does the Impax case compare with a litigated patent challenge?

Factor	Genzyme v. Impax	Merits-tested Hatch-Waxman case
Patent validity ruling	None publicly reported	Court decides validity
Infringement ruling	None publicly reported	Court compares claims with ANDA product
Settlement terms	Not fully public	Not applicable
Precedential value	Limited	Potentially significant
Generic entry timing	Controlled by settlement and regulatory status	Controlled by judgment, appeal, or settlement
Patent-strength signal	Commercially meaningful but legally incomplete	More reliable if supported by findings

The principal analytical conclusion is that the case demonstrates successful enforcement leverage, not adjudicated patent strength. Investors and licensing teams should not treat the dismissal as confirmation that the patents would have survived a full validity challenge.

Was there biosimilar risk?

No. Sevelamer carbonate is a synthetic polymeric small-molecule pharmaceutical product, not a biologic subject to the biosimilar pathway under the Public Health Service Act. The relevant competitors were ANDA-based generic applicants, not biosimilar applicants.

What is the current legal significance of the case?

Genzyme Corporation v. Impax Laboratories is primarily relevant for:

1. the use of Orange Book patents to delay generic sevelamer carbonate approval;
2. the commercial value of formulation and polymer-product claims;
3. the role of Paragraph IV litigation in negotiating generic-entry settlements; and
4. the distinction between a settlement dismissal and a merits determination.

The case does not establish a binding holding on the validity, enforceability, or infringement scope of U.S. Patent Nos. 6,858,203 or 7,014,846.

Key Takeaways

• The case involved Impax’s ANDA for generic sevelamer carbonate, the active ingredient in Renvela.
• Genzyme asserted Orange Book-listed patents, principally U.S. Patent Nos. 6,858,203 and 7,014,846.
• The action was a Paragraph IV Hatch-Waxman dispute filed in the District of Delaware under No. 1:09-cv-00653.
• The case ended through resolution and dismissal rather than a reported trial judgment.
• The patents had approximate expiration dates in May 2020 and December 2020, subject to applicable patent-term adjustments and related protections.
• Public materials do not disclose the complete settlement terms or establish the agreed generic launch date.
• The litigation supports a finding of meaningful commercial enforcement leverage, but not a definitive judicial finding that the asserted patents were valid and infringed.
• Sevelamer carbonate faced generic, not biosimilar, competition.

FAQs

Did Impax win or lose Genzyme’s Renvela patent case?

Neither side received a reported merits judgment. The case was resolved and dismissed, so the public record does not establish a judicial winner on validity or infringement.

What was the ANDA number filed by Impax for generic Renvela?

The publicly available case materials identifying the civil action do not reliably establish the complete ANDA number. The litigation record confirms that Impax filed an ANDA for generic sevelamer carbonate.

Did the Impax settlement allow generic Renvela before patent expiry?

The complete settlement terms and any agreed entry date are not publicly established in the cited litigation record. The commercial entry date cannot be inferred solely from the dismissal.

Were Genzyme’s Renvela patents composition patents or formulation patents?

They covered sevelamer carbonate pharmaceutical products and related formulation characteristics. Their practical scope depended on the asserted claims and the product described in Impax’s ANDA.

Could a later generic applicant rely on the Impax case to invalidate Renvela patents?

No. A settlement dismissal does not invalidate the patents and does not create a binding finding of non-infringement. Later applicants would need to develop their own invalidity, unenforceability, or non-infringement positions.

References

1. U.S. Food and Drug Administration. (2007). Renvela (sevelamer carbonate) prescribing information. FDA.

2. U.S. Patent No. 6,858,203. (2005). Sevelamer carbonate pharmaceutical compositions. U.S. Patent and Trademark Office.

3. U.S. Patent No. 7,014,846. (2006). Sevelamer carbonate. U.S. Patent and Trademark Office.

4. Genzyme Corporation v. Impax Laboratories, Inc., No. 1:09-cv-00653, U.S. District Court for the District of Delaware.

5. Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.